Item 8.01 Other Events.



Except where the context otherwise requires, all references in this Current
Report on Form 8-K ("Form 8-K") and the related exhibits attached hereto to the
"Company", "we", "us", "our" or similar words or phrases are to Bausch Health
Companies Inc. and its subsidiaries, taken together.

On August 3, 2021, the Company announced its intentions to conduct an initial
public offering ("IPO") of its aesthetic medical device business, Global Solta
("Solta") (the "Solta IPO"). In connection with the planned separation of its
Solta business into an independent publicly traded entity from the remainder of
Bausch Health Companies Inc., the Company has begun managing its operations in a
manner which is consistent with the organizational structure of the two separate
entities as proposed by the Solta IPO. As a result, during the first quarter of
2022, the Company's Chief Executive Officer ("CEO"), who is the Company's Chief
Operating Decision Maker, commenced managing the business differently through
changes in its operating and reportable segments, which necessitated a
realignment of the Company's historical segment structure. This realignment is
consistent with how the Company's CEO currently: (i) assesses operating
performance on a regular basis, (ii) makes resource allocation decisions and
(iii) designates responsibilities of his direct reports. Pursuant to these
changes, effective in the first quarter of 2022, the Company operates in the
following reportable segments: (i) Bausch + Lomb, (ii) Salix, (iii)
International (formerly International Rx), (iv) Solta Medical and (v)
Diversified Products. The new segment structure does not impact the Company's
reporting units but realigns the two reporting units of the former Ortho
Dermatologics segment whereby its medical dermatology reporting unit (Ortho
Dermatologics) is now part of the current Diversified Products segment and the
Solta reporting unit is now the sole reporting unit of the new Solta Medical
segment. All segment revenues and segment profits for the periods presented have
been recast to conform to the 2022 reportable segment structure.

We began to report under our new structure effective with the filing of our
Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2022,
filed with the United States Securities and Exchange Commission ("SEC") and with
the Canadian Securities Administrators on SEDAR at www.sedar.com on May 10,
2022. This Form 8-K updates and supersedes the information in Items 7 and
15(a)(1) of our Annual Report on Form 10-K for the year ended December 31, 2021
("2021 Form 10-K") to reflect retrospective application of the new segments and
reclassified historical results to conform to the new segment presentation.
These adjustments had no impact on the Company's consolidated operating results,
cash flows or equity. Except as specifically provided, the information in this
Form 8-K does not reflect any event or development occurring after February 23,
2022, the date we filed the 2021 Form 10-K. For a discussion of events and
developments subsequent to the filing of the Form 10-K, please refer to our
filings with the SEC and the Canadian Securities Administrators on SEDAR since
that date. In our Quarterly Report on Form 10-Q for the quarterly period ended
March 31, 2022, we adjusted the unaudited consolidated financial statements as
of and for the three months ended March 31, 2022 and 2021 to reflect the
retrospective application of our new segments. Accordingly, we are filing this
Form 8-K so that our annual financial statement information for the three (3)
years prior to January 1, 2022 incorporated by reference in any document that we
have filed or may file from time to time with the SEC or with the Canadian
Securities Administrators on SEDAR would reflect our current segment
presentation.

Item 9.01. Financial Statements and Exhibits.



(d)  Exhibits

Exhibit No.                  Description
  23*                          Consent of Independent Registered Public Accounting Firm
  99.1*                        Item 7. Management's Discussion and Analysis

of Financial Condition and


                             Results of Operations with Retrospective

Segment Changes of the 2021 Form


                             10-K
  99.2*                        Item 15.(a)(1) The consolidated financial statements required to be
                             filed in the Annual Report on Form 10-K with Retrospective Segment
                             Changes of the 2021 Form 10-K
101.SCH*                     XBRL Taxonomy Extension Schema Document
101.CAL*                     XBRL Taxonomy Extension Calculation Linkbase Document
101.LAB*                     XBRL Taxonomy Extension Label Linkbase Document
101.PRE*                     XBRL Taxonomy Extension Presentation Linkbase Document
101.DEF*                     XBRL Taxonomy Extension Definition Linkbase Document
104*                         Cover Page Interactive Data File (formatted as Inline XBRL and contained
                             in Exhibit 101)

____________________________________

--------------------------------------------------------------------------------

* Filed herewith.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses